Paper Details

  1. Home
  2. Paper Details

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.

Author: BeltmanJeri, GiordanoHeidi, HardingThomas C, LiaoMingxiang, MaloneyLara, SimmonsAndrew D, XiaoJim J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Rucaparib is a PARP inhibitor used to treat recurrent ovarian cancer and metastatic castration-resistant prostate cancer. It is taken orally twice a day and has a manageable safety profile, with the most common side effects being fatigue and nausea. Rucaparib is moderately bioavailable and can be taken with or without food. It is metabolized and excreted by the kidneys and liver.
Paper Details　
Original Abstract of the Article :
Rucaparib is an oral small-molecule poly(ADP-ribose) polymerase inhibitor indicated for patients with recurrent ovarian cancer in the maintenance and treatment settings and for patients with metastatic castration-resistant prostate cancer associated with a deleterious BRCA1 or BRCA2 mutation. Rucapa...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652254/

データ提供：米国国立医学図書館（NLM）

Rucaparib: A Promising Treatment for Ovarian and Prostate Cancer

The fight against cancer is constantly evolving, with new therapies emerging to combat these challenging diseases. This research provides a comprehensive overview of rucaparib, a novel poly(ADP-ribose) polymerase inhibitor, focusing on its clinical pharmacokinetics, pharmacodynamics, and safety profile.

Understanding Rucaparib: Pharmacokinetics, Pharmacodynamics, and Safety

The research summarizes the key characteristics of rucaparib, including its absorption, distribution, metabolism, and excretion. It also provides insights into how rucaparib interacts with other drugs and identifies potential side effects.

A New Weapon in the Arsenal Against Cancer: Rucaparib

This study offers valuable information for healthcare professionals seeking to understand the potential of rucaparib for treating ovarian and prostate cancer. It's like discovering a new oasis in the desert of cancer research, offering a promising new treatment option for patients battling these challenging diseases.

Dr. Camel's Conclusion

This research provides a thorough analysis of rucaparib, highlighting its potential as a valuable treatment option for ovarian and prostate cancer. By understanding its pharmacokinetics, pharmacodynamics, and safety profile, clinicians can make informed decisions about its use, maximizing patient benefit while minimizing the risk of adverse events.

Date :
  1. Date Completed 2022-11-15
  2. Date Revised 2023-09-18
Further Info :

Pubmed ID

36107395

DOI: Digital Object Identifier

PMC9652254

Related Literature

Article Analysis
・Effects of rucaparib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.